drugset / Trial / NCT00815594

Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

NCT00815594

Phase 4 Unknown 30 enrolled Capital Medical University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Timeline

Start
2008-12
Primary completion
2009-03
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 1.25 mg Subcutaneous

Indications